Skip to main content

Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users

This is a preview of subscription content, access via your institution.

References

  1. Caine DB, Langston JW, Martin WRW (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317:246–248

    Google Scholar 

  2. Davis GC, Williams AC, Markey SP (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1:249–254

    Google Scholar 

  3. Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can Med Assoc J 165:917–928

    CAS  Google Scholar 

  4. Langston JW, Ballard P, Tetrud JW, Irwin L (1983) Chronic Parkinsonism in humans due to a product of meperidine-analogue synthesis. Science 219:979–980

    Google Scholar 

  5. Langston JW, Ballard P (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and pathogenesis of Parkinson's disease. Can J Neurol Sci 11:160–165

    Google Scholar 

  6. McCann UD, Slate SO, Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Drug Safety 15:107–115

    CAS  PubMed  Google Scholar 

  7. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139:261–268

    Article  CAS  PubMed  Google Scholar 

  8. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy users. Hum Psychopharmacol 17:309–312

    Article  CAS  PubMed  Google Scholar 

  9. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277

    Google Scholar 

  10. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297:2260–2263

    Article  CAS  PubMed  Google Scholar 

  11. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19–24

    CAS  PubMed  Google Scholar 

  12. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2003) Increased intensity of ecstasy and polydrug use in the more experienced ecstasy users. Addict Behav (in press)

  13. Snyder SH (1984) Clues to aetiology from a toxin. Nature 311:514

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to A. C. Parrott.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Parrott, A.C., Buchanan, T., Heffernan, T.M. et al. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167, 449–450 (2003). https://doi.org/10.1007/s00213-003-1447-5

Download citation

Keywords

  • MPTP
  • Ecstasy
  • MDMA
  • Heavy User
  • Ecstasy User